Find information on thousands of medical conditions and prescription drugs.

Lovenox

In medicine, low molecular weight heparin (LMWH) is a class of medication used as an anticoagulant in diseases that feature thrombosis, as well as for prophylaxis in situations that lead to a high risk of thrombosis. more...

Home
Diseases
Medicines
A
B
C
D
E
F
G
H
I
J
K
L
Labetalol
Lacrisert
Lactitol
Lactuca virosa
Lactulose
Lamictal
Lamisil
Lamivudine
Lamotrigine
Lanophyllin
Lansoprazole
Lantus
Lariam
Larotid
Lasix
Latanoprost
Lescol
Letrozole
Leucine
Leucovorin
Leukeran
Levaquin
Levetiracetam
Levitra
Levocabastine
Levocetirizine
Levodopa
Levofloxacin
Levomenol
Levomepromazine
Levonorgestrel
Levonorgestrel
Levophed
Levora
Levothyroxine sodium
Levoxyl
Levulan
Lexapro
Lexiva
Librium
Lidocaine
Lidopen
Linezolid
Liothyronine
Liothyronine Sodium
Lipidil
Lipitor
Lisinopril
Lithane
Lithobid
Lithonate
Lithostat
Lithotabs
Livostin
Lodine
Loestrin
Lomotil
Loperamide
Lopressor
Loracarbef
Loratadine
Loratadine
Lorazepam
Lortab
Losartan
Lotensin
Lotrel
Lotronex
Lotusate
Lovastatin
Lovenox
Loxapine
LSD
Ludiomil
Lufenuron
Lupron
Lutropin alfa
Luvox
Luxiq
Theophylline
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Heparin is a naturally-occurring polysaccharide that inhibits coagulation, the process whereby thrombosis occurs. In nature, heparin consists of molecular chains of varying lengths, or molecular weights. Heparin derived from natural sources (including intestine) can be administered therapeutically to prevent thrombosis (see anticoagulation). However, the effects of natural, or unfractionated, heparin can be difficult to predict. After a standard dose of unfractionated heparin, coagulation parameters must be monitored very closely to prevent over- or under-anticoagulation.

Low molecular weight heparin, in contrast, consists of only short chains of polysaccharide, obtained by the deaminative hydrolysis of unfractionated heparin. Nitrous acid selectively cleaves the glycosidic bonds of the heparin with formation of di, tetra, hexa and higher saccharides terminated with 2,5-anhydro-D-mannose (AM) residues as reducing terminal groups. Having a lower average molecular weight means that a given dose of LMWH will be absorbed more predictably, leading to overall more predictable anticoagulation. It is also more selective for factor Xa and has less effect on thrombin.

Its differences with unfractioned heparin are:

  • Average molecular weight: heparin is about 20000 Da and LMWH is about 3000 Da
  • No need for monitoring of the APTT coagulation parameter
  • Possibly a smaller risk of bleeding
  • Smaller risk of osteoporosis in long-time use
  • Smaller risk of heparin-induced thrombocytopenia, a feared side-effect of heparin.

Because it can be given subcutaneously and does not require aPTT monitoring, LMWH permits outpatient treatment of conditions such as deep vein thrombosis or pulmonary embolism that previously mandated inpatient hospitalization for unfractionated heparin administration

The use of LMWH needs to be monitored closely in patients at extremes of weight or in patients with renal dysfunction. An anti-factor Xa activity may be useful for monitoring anticoagulation. Given its renal clearance, LMWH may not be feasible in patients who have end stage renal disease.

Makes of LMWHs include:

  • Bemiparin (Zibor®)
  • Dalteparin (Fragmin®)
  • Enoxaparin (Clexane® and Lovenox®)
  • Nadroparin (Fraxiparin® and Fraxodi®)
  • Tinzaparin (Innohep®)
  • Several others

Reference

  • Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98. PMID 9278467.

Read more at Wikipedia.org


[List your site here Free!]


Lovenox now available for acute deep-vein thrombosis treatment
From Drug Store News, 2/15/99

The FDA has approved Lovenox as the first low-molecular weight heparin available for the outpatient treatment of acute deep-vein thrombosis without pulmonary embolism, and for the inpatient treatment of acute deep-vein thrombosis with or without pulmonary embolism. Both indications require Lovenox be administered in conjunction with warfarin sodium. According to RhonePoulenc Rorer, this is the first time patients diagnosed with deep-vein thrombosis can be treated in the hospital or in their own homes. Those patients treated at home receive a subcutaneous injection of Lovenox twice a day; patients receiving in-hospital treatment are treated once or twice daily. Typically, deep-vein thrombosis is treated with unfractionated heparin, which must be given to the patient by continuous intravenous infusion, requiring several days of hospitalization and routine blood tests to monitor drug activity. According to a study done at Kaiser Permanente Medical Center, there was a clear economic advantage associated with usi ng Lovenox in the outpatient setting; by using Lovenox at home, estimated cost savings was $547 per patient.

COPYRIGHT 1999 Lebhar-Friedman, Inc.
COPYRIGHT 2000 Gale Group

Return to Lovenox
Home Contact Resources Exchange Links ebay